Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for Antimuscarinic Delirium
NCT06382649Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of rivastigmine in anticholinergic delirium, sponsored by Washington University School of Medicine. Started Jun 2026; status: recruiting.
02
Drugs
rivastigmine
03
Conditions
anticholinergic delirium
Beyond the preview
Go deeper on NCT06382649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06382649.